To identify treatment options for LQTS, we first implemented the high-throughput Tl+-flux trafficking assay, which revealed hundreds of drugs that increase function in 2 trafficking-deficient Kv11.1 variants. This evidence concerns the gene KCNH2 and familial long QT syndrome.